The CCI has finalised its view on the mega deal, also the first transaction that was subject to public scrutiny, and the same has been conveyed to the concerned parties.      

The deal, which CCI has prima-facie found to be in violation of competition norms, was inked in April this year and has been awaiting clearance from the competition watchdog since then.

Sources said the regulator is now awaiting response from the parties on the suggested changes.

Among others, CCI is believed to have suggested divestment of some brands in order to comply with competition norms, they added.

Sun Pharma-Ranbaxy transaction, which would create the country's largest pharmaceutical company, had come under close scrutiny of CCI after it was found prima-facie that the "combination is likely to have an appreciable adverse effect on competition".

The combined entity would have operations in 65 countries, 47 manufacturing facilities across 5 continents, and a significant platform of speciality and generic products marketed globally. The deal is also the first one where the commission sought public comments.

Major issues examined by CCI on the deal are with respect to the molecules market.

The public scrutiny of the deal, which would create the fifth largest speciality generics company in the world, ended on September 24.

This big ticket deal in the pharma space is also the first M&A transaction to have gone through public scrutiny.

Latest News  from Business News Desk